Antiviral and Antibiotic Drug Developers are scientists and researchers focused on creating medications to combat infections caused by viruses and bacteria. Their work involves identifying potential drug targets within pathogens and designing molecules that can inhibit their growth or replication. For antiviral drugs, developers focus on viruses like HIV, influenza, and SARS-CoV-2, while antibiotic developers aim to treat bacterial infections such as tuberculosis, pneumonia, and urinary tract infections. By understanding the mechanisms of how these pathogens affect the body, they develop drugs that can specifically target and disrupt key processes, thereby preventing or treating infections
These experts also face the challenge of antimicrobial resistance (AMR), where bacteria evolve to become resistant to antibiotics. Therefore, a significant part of their work involves developing new classes of antibiotics that can overcome resistance, ensuring that effective treatments remain available. Antiviral and antibiotic drug developers collaborate with clinical researchers to test new medications through clinical trials, ensuring their safety and efficacy. Their work is critical in the fight against infectious diseases, as they continually strive to develop more effective, safe, and accessible treatments to improve public health outcomes and manage the growing threat of resistant pathogens. In addition to developing new drugs, antiviral and antibiotic drug developers also focus on optimizing existing treatments to enhance their effectiveness and minimize side effects.
 
                                 
                                 
                                 
                                 
                                 
                                 
                             
                             
                             
                            
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain
Title : Mathematical modeling of COVID-19 dynamics in a West African context
Christabel Emaeyak James, University of Glasgow, United Kingdom
Title : Severe influenza and other related respiratory infection cases during Omicron era in Japan
Masafumi Seki, Saitama Medical University International Medical Center, Japan